REGENERON PHARMACEUTICALS (REGN) Stock News
NASDAQ:REGN - Nasdaq - US75886F1075 - Common Stock - Currency: USD
REGN Latest News, Press Relases and Analysis
Market Monitor News June 02 (Ulta Beauty, ZScaler UP - GAP, Regeneron DOWN)
Wall Street Wraps Up Strong May with Caution as Trade Tensions Resurface
Top S&P500 movers in Friday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session.
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group.
Mentions: MAIA
23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer
Regeneron previously won 23andMe at auction. But now the company wants to reopen bidding with an offer from its former CEO.
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.
23andMe Sets New Auction With $305 Million New Bid From Ex-CEO
Bankrupt genetic analysis company 23andMe will hold a second auction for its cache of DNA data with an opening bid of $305 million from group lead by the company’s former chief executive officer, Anne Wojcicki.
23andMe seeks new bids after $305 million offer from its co-founder
NEW YORK (Reuters) -Bankrupt genetic testing company 23andMe told a U.S. bankruptcy judge on Wednesday that it wants to re-open bidding on its assets, including customers' genetic data, after receiving a $305 million offer from its co-founder Anne Wojcicki. 23andMe had previously selected a $256 million bid from Regeneron Pharmaceuticals as the lead offer after a bankruptcy auction concluded in May. But it received a later bid from TTAM Research Institute, a new nonprofit founded by Wojcicki, and asked U.S. Bankruptcy Judge Brian Walsh in St. Louis, Missouri, to be allowed to re-engage with potential buyers after determining that TTAM had sufficient financing to proceed with the higher offer.
Mentions: ME
23andMe Judge Questions Limits for New Auction for Bankrupt Firm
The judge overseeing the bankruptcy of 23andMe questioned the limits proposed for a second auction that is designed to push bids higher than a current $256 million offer from Regeneron Pharmaceuticals for the genetic-testing firm.
Elizabeth Warren Says Trump 'Approved' The Largest Meat Company In World To Be Listed On NYSE Ignoring Corruption And Bribery History, Demands Answers
Sen. Elizabeth Warren (D-Mass.) is once again calling out corruption in the Trump Administration, following a questionable decision made by the U.S. Securities and Exchange Commission. What Happened: On Monday, Warren shared a video on X questioning ...
Surprising guidance sends CrowdStrike stock reeling
Here's why Crowdstrike shares are tumbling.
Regeneron makes obesity push; Atai, Alto ink brain drug deals
Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.
Regeneron price target lowered to $600 from $800 at BMO Capital
BMO Capital lowered the firm’s price target on Regeneron (REGN) to $600 from $800 and keeps an Outperform rating on the shares. The firm is updating its model following “disappointing” results for itepekimab in COPD, noting that with only one of the two phase 3 studies reaching statistical significance and the path forward for approval more difficult, it is lowering its probability of success for itepekimab to 0%, the analyst tells investors in a research note. Published first on TheFly – the ul
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today
The company had some encouraging regulatory news to report. It concerned a dermatitis drug the biotech is currently developing. Investors were surely discovering drug discovery company AbCellera Biologics (NASDAQ: ABCL) as the trading week kicked off on Monday.
Regeneron To Buy Licensing Rights For China-Developed Investigational Obesity Drug For $2B: Retail Sees Stock Hitting $500
Separately, Regeneron on Monday also announced positive interim data from its ongoing Phase 2 trial investigating novel combinations of semaglutide and Trevogrumab with or without garetosmab for the treatment of obesity.
Sanofi to Acquire Blueprint Medicines for up to $9.5 Billion to Expand Immunology Portfolio
Sanofi (SNY) agreed to acquire biopharmaceutical company Blueprint Medicines (BPMC) in a deal worth
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
Mentions: CRSP
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
CRISPR Therapeutics has the potential to generate significant breakthroughs in gene editing. Regeneron's biggest growth driver is still performing well, and it is developing newer medicines. For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: CRISPR Therapeutics (NASDAQ: CRSP) and Regeneron Pharmaceuticals (NASDAQ: REGN).
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in...
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
3 Best Growth Stocks to Buy in June
Growth investors have had to work harder than usual to find winners in 2025. With the S&P 500 essentially flat year to date amid President Trump's global trade reset and persistent inflation concerns, the easy gains of prior years have evaporated. While the average stock treads water, companies with genuine competitive advantages and exposure to secular growth themes are posting triple-digit gains.
German financial watchdog: AI is helping to catch market abuse
FRANKFURT (Reuters) -Germany's financial regulator BaFin is using artificial intelligence to help it spot market abuse and suspicious patterns in trading, increasing the chances of catching offenders, a top official warned on Monday. BaFin President Mark Branson said the supervisor had started using artificial intelligence last year in its alert and market analysis system. "We can already see from this that the results of this analysis system have become more accurate," Branson said at a conference.
Trump tariffs deal major blow to European steelmakers, Salzgitter CEO warns
DUESSELDORF/FRANKFURT (Reuters) -Salzgitter, Germany's second-biggest steelmaker, warned on Monday that Washington's tariff policy was dealing a severe blow to European industry, after the U.S. administration unveiled plans to double steel import levies to 50%. According to Germany's steel association, the United States accounted for around a fifth, or 4 million metric tons, of European steel exports outside of the EU, making it the sector's most important export market. "The erratic tariff policy of the USA is hitting Europe's economy hard - especially Germany," Salzgitter CEO Gunnar Groebler said in a statement.
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated...
Why Newsmax Stock Is Crashing Today
The SEC has given its blessing to certain Newsmax shareholders, allowing them to sell their shares on the open market. As many as 121 million shares can now be sold, significantly more than were already publicly traded. Shares of Newsmax Media (NYSE: NMAX) are plunging on Friday.
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Curious about which S&P500 stocks are generating unusual volume on Friday? Find out below.
Discover which S&P500 stocks are making waves on Friday.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.
Friday's session: gap up and gap down stock in the S&P500 index
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Friday to uncover the stocks that are gapping in the S&P500 index.
Traders are paying attention to the gapping stocks in Friday's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
These S&P500 stocks are moving in today's pre-market session
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
What's going on in today's session: S&P500 movers
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.